AdventRx Adds SVP

Gregory D. Gorgas has been named senior vice president, Commercial at AdventRx Pharmaceuticals. Mr. Gorgas brings more than 25 years of experience in drug product commercialization, with an emphasis in launching new products, building commercial infrastructure and leading start-up operations.  He was a key contributor to the blockbuster success of Rituxan while at Biogen Idec, where most recently he led global marketing for the oncology franchise.  

“After consulting with AdventRx for over 18 months, I have deep familiarity with the company and its product candidates and believe in the promise and commercial potential of Exelbine,” said Mr. Gorgas. “I’m thrilled to join the AdventRx team and look forward to making Exelbine available to patients, should it be approved.” Exelbine is a novel formulation of viorelbine, a treatment for non-small cell lung cancer.

“Greg’s first-hand experience successfully launching four first-in-class products and strong relationships in the oncology community make him a great addition to our team.  Importantly, his understanding of the multi-source marketplace will prove valuable as we continue to prepare for the launch of Exelbine,” said Brian M. Culley, AdventRx’s chief executive officer.